ResultsIQ

ResultsIQ › Latest results › Procter & Gamble Health Limited

Procter & Gamble Health Limited investor meet summary

NSE: PGHL · BSE: 500126

Investor meet of 18 Jun 2026, summarised by AI from the filing.

P&G Health reported FY26 sales close to ₹1400 cr, up 16%, and PAT of ₹327 cr, up 30%, while declining to give forward guidance.

Key takeaways

  1. FY26 results Sales close to ₹1400 cr, up 16%, and profit after tax ₹327 cr, up 30%, versus the comparable period last year.
  2. Guidance Management refrained from sharing forward-looking statements, including annual guidance and FY27 EBITDA margin expectations.
  3. Innovations Three launches this fiscal year collectively contributed early single digit points of growth to the overall business.
  4. Distribution GTM model added nearly 30,000 pharmacies and HCPs to overall coverage in the last 2-3 years.
  5. Evion, Polybion An analyst cited IQVIA data showing de-growth in FY26; management said there is always an opportunity to grow further.

Original filing on BSE

Procter & Gamble Health Limited Q1 FY27 results

As filed: Revenue ₹364 cr (+7% year on year), EBITDA ₹99.6 cr (+11% year on year), PAT ₹96.2 cr (+9% year on year), EBITDA margin 27.4% (+84 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹370 cr (+19% year on year), EBITDA ₹136 cr (+67% year on year), PAT ₹94.6 cr (+55% year on year), EBITDA margin 36.6% (+1,000 bps). Score 81 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA growth was well above it; profit growth was in line with it. EBITDA margin rose 1000 bps year on year. Profit rose ₹33.6 cr on a year ago, more than the ₹14.0 cr it added the year before. Share price after the results: +10.3% in 30 days (Nifty 500: +0.9%).
  • Q3 FY26: Revenue ₹374 cr (+21% year on year), EBITDA ₹110 cr (−11% year on year), PAT ₹77.6 cr (−15% year on year), EBITDA margin 29.6% (−1,000 bps). Score 44 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 1000 bps year on year. Profit fell 13% from last quarter. Share price after the results: −6.8% in 28 days (Nifty 500: −4.0%).
  • Q2 FY26: Revenue ₹325 cr (+4% year on year), EBITDA ₹120 cr (+5% year on year), PAT ₹89.0 cr (+9% year on year), EBITDA margin 36.9% (+50 bps). Score 44 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were below it. EBITDA margin rose 50 bps year on year. Revenue fell 4% from last quarter. Share price after the results: −5.8% in 30 days (Nifty 500: +0.7%).
  • Q1 FY26: Revenue ₹339 cr (+19% year on year), EBITDA ₹90.0 cr (+88% year on year), PAT ₹66.0 cr (+288% year on year), EBITDA margin 26.6% (+965 bps). Score 90 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 965 bps year on year. Share price after the results: +8.0% in 28 days (Nifty 500: −2.0%).
  • Q4 FY25: Revenue ₹311 cr (+23% year on year), EBITDA ₹81.0 cr (+19% year on year), PAT ₹61.0 cr (+30% year on year), EBITDA margin 26.1% (−94 bps). Score 71 of 100, Above trend. Revenue and profit growth were well above the company's own trend; EBITDA growth was above it. EBITDA margin fell 94 bps year on year. Profit fell 33% from last quarter. Share price after the results: +1.5% in 29 days (Nifty 500: +3.3%).
  • Q3 FY25: Revenue ₹310 cr (0% year on year), EBITDA ₹124 cr (+22% year on year), PAT ₹91.0 cr (+26% year on year), EBITDA margin 40.0% (+710 bps). Score 65 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were above it. EBITDA margin rose 710 bps year on year.
  • Q2 FY25: Revenue ₹313 cr (+3% year on year), EBITDA ₹114 cr (+30% year on year), PAT ₹82.0 cr (+24% year on year), EBITDA margin 36.4% (+757 bps). Score 61 of 100, In line with trend. EBITDA margin rose 757 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Procter & Gamble Health Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.